KANGHUI PHARMACEUTICAL(SH:603139) Xin Lang Cai Jing·2025-11-11 05:24Core Viewpoint - Kanghui Co., Ltd. has shown a significant stock price increase of 64.07% year-to-date, indicating strong market interest and potential growth in the pharmaceutical sector [2]. Financial Performance - As of September 30, Kanghui Co., Ltd. reported a revenue of 356 million yuan, a year-on-year decrease of 11.97%, and a net profit attributable to shareholders of -133 million yuan, reflecting a substantial decline of 246.07% [2]. - The company has cumulatively distributed 54.23 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - The stock price of Kanghui Co., Ltd. rose by 2.04% on November 11, reaching 23.56 yuan per share, with a trading volume of 23.57 million yuan and a turnover rate of 1.01% [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent instance on June 16, where it recorded a net purchase of 7.7 million yuan [2]. Shareholder Information - As of September 30, the number of shareholders for Kanghui Co., Ltd. was 9,458, a decrease of 21.15% from the previous period, while the average circulating shares per person increased by 26.82% to 10,560 shares [2]. Business Overview - Kanghui Co., Ltd., established on December 24, 2009, and listed on April 21, 2017, is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, with its main business revenue composition being 60.68% from pharmaceutical manufacturing and 36.79% from pharmaceutical distribution [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the traditional Chinese medicine sub-sector [2].